Response to Jovanovič for the Comments on Our Study “Insulin Glulisine Compared to Insulin Aspart and to Insulin Lispro Administered by Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: A Randomized Controlled Trial”
Restricted accessLetterFirst published online August, 2011
Response to Jovanovič for the Comments on Our Study “Insulin Glulisine Compared to Insulin Aspart and to Insulin Lispro Administered by Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: A Randomized Controlled Trial”
van BonAC, BodeBW, Sert-LangeronC, DevriesJH, CharpentierG. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes Technol Ther, 2011; 13:607–614.
2.
HoogmaRP, SchumickiD. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Horm Metab Res, 2006; 38:429–433.
